Science Daily (07/31/2012)
Researchers out of the Mayo Clinic in Florida have discovered that two drugs, romidepsin (Istodax) and decitabine (Dacogen), used in tandem can help fight cancers where the tumor-suppressor gene secreted frizzled related protein one (sFRP1) is disabled -- as is the case in the most common forms of breast and kidney cancer. These drugs help to jump start the gene, and the gene in turn halts the growth new tumor cells and kills any existing tumor cells. Both of the drugs are FDA-approved to treat blood cancer, but this was the first study to that showed how effective mixing the drugs together could be when combating cancers where sFRP1 is nonfunctional.

Read the complete article